Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060979 | 0.88 | NOTUM (0.79) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL23451560 | 0.84 | NOTUM (1.00) | NOTUMP2RX7L3MBTL1 | |
| SCHEMBL13526965 | 0.81 | NOTUM (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL21157730 | 0.81 | NOTUM (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL19211396 | 0.79 | NOTUM (1.00) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL19211467 | 0.78 | P2RX7 (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL19211427 | 0.78 | NOTUM (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL30723667 | 0.77 | NOTUM (0.72) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL9969543 | 0.77 | NOTUM (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL15578596 | 0.77 | NOTUM (0.62) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885P2RX7 3985/4885KDM4E 3907/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885P2RX7 2289/4885KDM4E 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.